EDIT vs MCK · rev $32.3M vs P/E 20, rev $403.43B
Editas Medicine Inc (EDIT) versus McKesson Corporation (MCK) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
McKesson Corporation (MCK) is a medical distribution company listed on NYSE.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported MCK revenue for 2026-03-31 was $403.43B. Net income was $4.76B. Revenue was up 12.4% from 2025-03-31 to 2026-03-31. MCK currently screens at market cap $91.30B and trailing P/E 20.3.
EDIT currently screens at market cap $375.2M. MCK currently screens at market cap $91.30B and trailing P/E 20.3.
Not investment advice. Open the EDIT and MCK stock pages for the full models.
Not investment advice.